Review



podocalyxin clone 3d3 novus biologicals  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals podocalyxin clone 3d3 novus biologicals
    Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); <t>Podocalyxin</t> (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).
    Podocalyxin Clone 3d3 Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d3+novus+biologicals+nbp2/Podocalyxin+Like+Antibody+(3D3)/pm37216114-213-14-17
    Average 93 stars, based on 10 article reviews
    podocalyxin clone 3d3 novus biologicals - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease."

    Article Title: Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease.

    Journal: iScience

    doi: 10.1016/j.isci.2023.106686

    Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); Podocalyxin (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).
    Figure Legend Snippet: Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); Podocalyxin (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).

    Techniques Used: Control, Next-Generation Sequencing, Marker, Transmission Assay, Western Blot, Isolation, Expressing, RNA Sequencing

    Related Articles

    Western Blot:

    Article Title: Comparison of urinary extracellular vesicle isolation methods for transcriptomic biomarker research in diabetic kidney disease.
    Article Snippet: Images were acquired using Jeol JEM-1400 (Jeol Ltd, Tokyo, Japan) operating at 80 kV, equipped with Gatan Orius SC 1000B CCD-camera (Gatan Inc., Pleasanton, CA) and using image size 20013078, 2020, 2, D ow nloaded from https://isevjournals.onlinelibrary.w iley.com /doi/10.1002/jev2.12038 by IN A SP - N E PA L , W iley O nline L ibrary on [30/12/2024]. .. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense BARREIRO et al. of TABLE Primary and secondary antibodies used for Western blotting Primary antibody Company Code Dilution Tamm-Horsfall protein Santa Cruz Biotechnology SC-20631 1:3000 Albumin Santa Cruz Biotechnology SC-58688 1:1000 Podocalyxin; clone 3D3 Novus Biologicals NBP2-25219 1:500 TSG-101 Santa Cruz Biotechnology SC-7964 1:400 CD9 Santa Cruz Biotechnology SC-13118 1:400 Secondary antibody Company Code Dilution Rabbit anti mouse Jackson Immuno Research 315-035-045 1:6000 Goat anti rabbit Jackson Immuno Research 111-035-045 1:6000 of 4008 × 2672 pixels. ..



    Similar Products

    podocalyxin clone 3d3 novus biologicals  (Novus Biologicals)
    93
    Novus Biologicals podocalyxin clone 3d3 novus biologicals
    Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); <t>Podocalyxin</t> (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).
    Podocalyxin Clone 3d3 Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d3+novus+biologicals+nbp2/Podocalyxin+Like+Antibody+(3D3)/pm37216114-213-14-17
    Average 93 stars, based on 1 article reviews
    podocalyxin clone 3d3 novus biologicals - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    3d3 novus biologicals nbp2  (Novus Biologicals)
    92
    Novus Biologicals 3d3 novus biologicals nbp2
    Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); <t>Podocalyxin</t> (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).
    3d3 Novus Biologicals Nbp2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d3+novus+biologicals+nbp2/Podocalyxin+Like+Antibody+(3D3)/pm33437407-81-72-73
    Average 92 stars, based on 1 article reviews
    3d3 novus biologicals nbp2 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); Podocalyxin (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).

    Journal: iScience

    Article Title: Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease.

    doi: 10.1016/j.isci.2023.106686

    Figure Lengend Snippet: Figure 1. Study design and Urinary extracellular vesicles (uEV) quality control (A) Study design for the next generation sequencing of uEV mRNAs to assess urine collections, quality and reproducibility (technical comparisons), origins of uEV transcripts (uEV on Tissue map), and discovery of candidate non-invasive markers for diabetic kidney disease (DKD marker candidates). (B–D) Transmission electron micrographs showing uEV of typical morphology and variable sizes; filamentous structures compatible with Tamm-Horsfall protein filaments are visible in the in-set B1. (E) Western blotting showing the presence of uEV-enriched markers CD9 and PDX in uEV preparations. (F) Representative electropherograms of RNA isolated from uEV and analyzed with bioanalyzer using Agilent Pico kit. An RNA peak between 25 and 200 nt was detected in all samples and with this characteristic shape passed quality control. (G) Examples showing signs of nucleic acid degradation (arrows) in uEV RNA samples and not passing quality control. 24 h (24h); albumin excretion rate (AER); blood pressure (BP); body-mass index (BMI); estimated glomerular filtration rate (eGFR); waist-to-hip ratio (WHR); Genotype-Tissue Expression (GTEx) project; glycated hemoglobin (HbA1C); Lymph Node Carcinoma of the prostate (LnCaP), macroalbuminuria (Macro); microalbuminuria (Micro); non-diabetic control (Control); normoalbuminuria (Normo); messenger RNA sequencing (mRNAseq); Podocalyxin (PDX), type 1 or type 2 diabetes (T1D, T2D); urinary extracellular vesicles (uEV); principal component analysis (PCA); single-nucleus RNA sequencing (snRNA-seq).

    Article Snippet: Antibodies Mouse monoclonal against CD9 Santa Cruz Cat# SC-13118; RRID: AB_627213 Mouse monoclonal against Podocalyxin (clone 3D3) Novus Biologicals Cat# NBP2-25219; RRID: N/A

    Techniques: Control, Next-Generation Sequencing, Marker, Transmission Assay, Western Blot, Isolation, Expressing, RNA Sequencing